Carbogen Amcis takes over Swiss plant to boost ADC offering

Carbogen Amcis has signed a long-term lease for an ADC unit in Vionnaz, Switzerland

Carbogen Amcis has expanded its operations in light of unrelenting demand for antibody-drug conjugate (ADC) services by signing a long-term lease for a facility in Switzerland.

Cabogen Amcis, a contract manufacturing organisation (CMO) owned by India-based Dishman Pharmaceuticals and Chemicals, this week signed a long-term lease agreement with chemicals and biotech firm Bachem to take over a high-containment unit in Vionnaz, Switzerland.

The facility is fully equipped for the development and small scale cGMP manufacture of highly potent drugs and drug-linkers - one of the main components of an ADC - Carbogen Amcis told and will help fulfill growing customer demand for ADC development and manufacture.

“In the last 18 to 24 months, the ADC market gained momentum, well beyond the demand we have experienced in the last 10 years, spurred by large pharma and small biotechs,” Dr. Alan Fischer, Director of Technology, told us.

“Clinical results have showed that ADCs can recognize and target cancer cells leading to their death with fewer side effects for the patient,” and was the main driver in both this expansion and an investment last year which saw the firm set up a dedicated clean room and clinical supply suite at its plant in Beubendorf, Switzerland.

The Vionnaz plant will complement Bubendorf, which caters to larger cGMP manufacture projects and, according to Fischer, supports the coupling of biological material and the drug-linker moiety in an aseptic environment.

The Vionnaz facility includes a process development laboratory, a dedicated QC laboratory and two production units fitted with reactors up to 30 L, as well as equipment for lyophilisation and chromatography.

Flexible manufacturing approach

Carbogen Amcis has over 200 customers on its books and therefore needs to be flexible with its chemistries and philosophies, especially for ADCs. “Therefore, we use equipment fit for purpose, depending on the project and customer needs,” Fischer said.

This includes single-use technology which, like other biomanufacturers, Carbogen Amcis is implementing alongside more traditional systems.

“For example, we have single-use equipment, bags, and reaction containers besides fixed installations like isolators, glove boxes, laminar flow benches, walk-in hoods and freeze dryers (with single use Lyogards, injection vials and syringes),” we were told.

“Tangential flow filtration and chromatography are supported by a mix of fixed installations (like pumps) and single project use columns (like the Biotage system for example), membranes and tubing.”

Related News

Swiss franc plunges - bad for Visp says Lonza

Swiss franc movement sees Roche, Novartis, Actelion and Lonza shares plummet

(Image: R Nial Bradshaw)

UK R&D firm patents biologics powder storage technique

Carbogen Amcis to buy GEA plant in Bubendorf (source Google)

Carbogen Amcis to buy GEA plant and convert it for API production

Competition not a concern says Carbogen Amcis CEO

Carbogen Amcis CEO: Competition in ADC sector not a concern

Carbogen Amcis invests in ADC capacity

Carbogen Amcis invests in ADC capacity

ADCs a big opportunity for Big Pharma say experts

Big Pharma business opportunities driving ADC boom say experts

ADC development often trial and error says expert

ADC complexity means CMO investment likely to continue says expert

Lonza adding single-use systems at its clinical ADC facility in Visp, Switzerland

ADC pipelines drive single-use expansion at Lonza's clinical facility

Talking ADCs with SAFC, Piramal and Catalent at CPhI Frankfurt

'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI

Related Products

See more related products